Saito Ryoichi, Moroi Seiji, Okuno Hiroshi, Ogawa Osamu
Departments of Urology, Kouka Public Hospital, Shiga Kobe City Central Hospital, Hyogo Kyoto National Hospital Faculty of Medicine, Kyoto University, Kyoto, Japan.
Int J Urol. 2004 Mar;11(3):171-4. doi: 10.1111/j.1442-2042.2003.00769.x.
Methylprednisolone sodium succinate (MPS) is widely used in the management of renal transplantation. Of interest is the rare occurrence of anaphylaxis and anaphylactoid reaction to MPS. We report on a patient who developed anaphylaxis following the intravenous administration of MPS during a renal transplant operation. Intracutaneous testing was carried out with MPS and a strong positive reaction was observed. Histamine and tryptase concentrations were high after the anaphylactic reaction. Including the present case, there have been 13 reports of anaphylactic or anaphylactoid reactions to MPS, occurring in renal transplant recipients. Clinicians should be aware of the potential risk of MPS administration. If transplant patients undergo skin testing against MPS prior to transplant, they may benefit from an alternative medication with other corticosteroids. To use MPS without severe adverse reactions, lower administration rates and dosages are very important.
甲泼尼龙琥珀酸钠（MPS）广泛应用于肾移植的管理。值得关注的是，对MPS发生过敏反应和类过敏反应的情况较为罕见。我们报告了一名患者，在肾移植手术期间静脉注射MPS后发生了过敏反应。用MPS进行了皮内试验，观察到强烈的阳性反应。过敏反应后组胺和类胰蛋白酶浓度升高。包括本病例在内，已有13例肾移植受者对MPS发生过敏或类过敏反应的报告。临床医生应意识到使用MPS的潜在风险。如果移植患者在移植前接受针对MPS的皮肤试验，他们可能会受益于使用其他皮质类固醇的替代药物。为了在使用MPS时不发生严重不良反应，降低给药速率和剂量非常重要。
